What Researchers Did
Researchers conducted a prospective, controlled study in rabbits and adult human volunteers at varying altitudes to validate a new plateau hyperbaric chamber for alleviating high altitude hypoxia.
What They Found
In rabbits, mean PaO2 significantly increased from 49.6 ± 1.9 mmHg to 70.3 ± 2.1 mmHg (P < 0.01) after hyperbaric treatment. Similarly, in human volunteers, mean PaO2 rose from 51.2 ± 2.3 mmHg to 71.5 ± 2.5 mmHg (P < 0.01), accompanied by significant decreases in respiratory rate, heart rate, and blood pressure (P < 0.01).
What This Means for Canadian Patients
This new hyperbaric chamber could offer a non-pharmacological option for individuals experiencing high altitude sickness. It may provide rapid relief from symptoms by improving oxygen levels and vital signs.
Canadian Relevance
There is no direct Canadian connection mentioned in this study.
Study Limitations
The abstract does not explicitly state limitations, but the study involved a specific population and environment, and the long-term efficacy was not assessed.